Trypanosomiasis, African Clinical Trial
Official title:
An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
This study evaluates the effectiveness of fexinidazole administered to patients with human African trypanosomiasis due to T. b. gambiense (g-HAT) at all stages of the disease. The aim of the present study is to provide additional information on the effectiveness and safety of fexinidazole and to assess its use under conditions as close as possible to those in real life, both in patients treated on an out-patient basis and in the hospital setting, depending on clinical status. Participants will receive fexinidazole oral treatment for 10 days. Regular blood draws and lumbar punctures will be performed over 18 months to confirm the cure of the disease. Other assessments will include the recording of adverse events, signs and symptoms of the disease, laboratory tests, vital signs, electrocardiograms. Treatment compliance, feasibility, and packaging acceptability will be thoroughly assessed in the participants receiving treatment at home. Those participants will complete questionnaires to check that instructions for fexinidazole administration are clear enough and followed correctly.
See attached protocol. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01483170 -
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
|
Phase 1 | |
| Terminated |
NCT00489658 -
Eflornithine + Nifurtimox Late-Stage Human African Trypanosomiasis (HAT)in West Nile, Uganda
|
Phase 2/Phase 3 | |
| Completed |
NCT03087955 -
Prospective Study on Efficacy and Safety of Acoziborole (SCYX-7158) in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense
|
Phase 2/Phase 3 | |
| Completed |
NCT02571062 -
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
|
Phase 1 | |
| Terminated |
NCT00330148 -
Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis
|
Phase 3 | |
| Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05645822 -
Screen and Treat Implementation for HAT Control
|
||
| Completed |
NCT05947604 -
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
|
Phase 1 | |
| Completed |
NCT01533961 -
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
|
Phase 1 | |
| Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
| Completed |
NCT00802594 -
A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis
|
Phase 2 | |
| Completed |
NCT00146627 -
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
|
Phase 3 |